High rifaximin out-of-pocket costs are associated with decreased treatment retention among patients with hepatic encephalopathy

BACKGROUND AND AIMS: Hepatic encephalopathy (HE) is associated with significant morbidity and mortality for those with cirrhosis. Despite the known benefits of rifaximin use for HE, treatment retention remains low. This study aimed to evaluate the impact of out-of-pocket (OOP) rifaximin cost on trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Aby, Elizabeth S., Shen, Tsung-Hua, Murugappan, Meena N., Stenehjem, David D., Leventhal, Thomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553020/
https://www.ncbi.nlm.nih.gov/pubmed/37534941
http://dx.doi.org/10.1097/HC9.0000000000000215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553020/
https://www.ncbi.nlm.nih.gov/pubmed/37534941
http://dx.doi.org/10.1097/HC9.0000000000000215

Ejemplares similares